Abstract:Abstract Background Gemcitabine/erlotinib treatment offers limited benefit in unselected patients with pancreatic ductal adenocarcinoma (PDAC). Development of skin rash has been associated with favorable outcomes in patients treated with gemcitabine/erlotinib. This study aimed to extend knowledge on the effectiveness of gemcitabine/erlotinib in metastatic PDAC in the context of clinical practice and with focus on skin rash. Methods This multicenter, non-interventional study enrolled 376 patients with metastatic PDAC receiving gemcitabine/erlotinib. The primary endpoint was overall survival (OS) in patients with skin rash versus no skin rash. Secondary endpoints included progression-free survival (PFS), treatment satisfaction and safety. All data were analyzed using descriptive statistics. Survival time and time to disease progression were estimated using the Kaplan-Meier method. Effectiveness endpoints were analyzed for subgroups by skin rash grade (no rash, rash grade 1, rash grade ≥ 2), duration of erlotinib treatment (≤8 weeks, > 8 weeks), Eastern Cooperative Oncology Group (ECOG) performance status at baseline (0–1, 2) and age (≤65 years, > 65 years). Results Within the full analysis set (FAS; N = 270), 48 patients (17.8%) developed grade 1 rash, 51 patients (18.9%) grade ≥ 2 rash, while 171 patients (63.3%) did not develop a rash. Median OS of all patients was 9.11 months with an OS of 9.93 months in rash-positive and 8.68 months in rash-negative patients. Median PFS was 5.06 months for rash-positive and 4.11 months for rash-negative patients. PFS was longer in patients with rash grade ≥ 2 and in older patients (> 65 years). Examination using a multivariate Cox proportional model revealed that an age > 65 years was associated with longer OS (hazard ratio 0.640; p = 0.0327) and PFS (hazard ratio 0.642; p = 0.0026). Out of the 338 patients in the SAF, 310 patients (91.7%) experienced at least one AE, and 176 patients (52.1%) experienced skin-related side effects, all of which were CTC grade 1 to 3. Conclusions Comparing rash-positive with rash-negative patients showed no significant difference in survival. While patients with rash grade ≥ 2 and older patients (independent of skin reactions) showed longer PFS, this did not translate into prolonged OS. The study did not reveal new safety signals. Trial registration ClinicalTrials.gov Identifier: NCT01782690 , retrospectively registered on 4 February 2013.

Respective Study of the Incidence of Skin Rash Induced by Domestic and Imported Gemcitabin

Differences between Domestic and Imported Gemcitabin in Hematologic Adverse Reactions

Pharmacokinetics and relative bioavailability of domestic vs imported cefpodoxime proxetil tablets in human body

Isotretinoin Erythromycin Gel in the Treatment of Acne Vulgaris: a Multicenter Randomized Parallel-Controlled Clinical Study

Studies on Bioequivalence of Ramipril Capsule in Healthy Volunteers

Analysis of 112 patients with adverse drug reactions induced by gemcitabine

Comparison of Pharmacokinetics, Efficacy and Toxicity Profile of Gemcitabine Using Two Different Administration Regimens in Chinese Patients with Non-Small-cell Lung Cancer

[Phase II Clinical Trial on Gemcitabine in the Treatment of Stage IIIB-IV Non-Small Cell Lung Cancer].

Pharmacokinetics and Relative Bioavailability of Imported and Domestic Thiamazole Tablets in Chinese Healthy Volunteers

Domestic Cetirizine Tablet in Treating Perennial Allergic Rhinitis

A Randomized Controlled Study of Domestic and Imported Cefotiam in the Treatment of Bacterial Infections

Investigation of 134 reports of drug dermatitis in our hospital

Topical Zhiyang Pingfu Liquid for Moderate to Severe Skin Rash Associated With EGFRIs: A double-blinded randomized controlled trial

Study on bioequivalence of domestic and imported glipizide tablets

Studies on Bioequivalence of Domestic Diisopropylamine Dichloroacetate Tablet and Capsule in Healthy Volunteers

Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study

Experimental Study on Allergic and Skin Irritation of Guci Powder in Rabbits

Clinical Experience of External Application of Clearing Heat and Removing Dampness in Relieving Grade 2 to 3 Rash Caused by Programed Cell Death Protein 1 (PD-1)/Programed Cell Death Ligand 1 (PD-L1) Inhibitors: A Single-Center Retrospective Study

Bioequivalence of Domestic and Imported Betahistine Mesylate Tablets in Healthy Volunteers

[Studies on Cutaneous Permeation in Vitro of Kushen Recipe Gel].

Pharmacokinetics study of gemcitabine and its metabolite in Chinese patients with malignant tumor